Sparsentan
 | |
| Names | |
|---|---|
| Trade names | Filspari |
| Clinical data | |
| Drug class | Endothelin and angiotensin II receptor blocker[1] |
| Main uses | Primary immunoglobulin A nephropathy.[1] |
| Side effects | Low blood pressure, swelling of the legs, high potassium, low red blood cells, liver problems[1] |
| Routes of use | By mouth |
| Typical dose | 200 to 400 mg OD[1] |
| External links | |
| AHFS/Drugs.com | Monograph |
| Legal | |
| License data |
|
| Legal status | |
Sparsentan, sold under the brand name Filspari, is a medication used to treat primary immunoglobulin A nephropathy.[1] Specifically it is used to reduce protein in the urine.[1] As of 2023, it is unclear if it affects long term kidney function.[1] It is taken by mouth.[1]
Common side effects include low blood pressure, swelling of the legs, high potassium, and low red blood cells.[1] Severe side effects may include liver problems.[1] Use in pregnancy may harm the baby.[1] It is an endothelin and angiotensin II receptor blocker.[1]
Sparsentan was approved for medical use in the United States in 2023.[1] It is estimated to cost about 170,000 USD per year in the United States as of 2023.[2]
Medical uses
Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.[1]
Dosage
It is started at 200 mg once per day and is increased to 400 mg once per day after two weeks.[1]
Society and culture
Legal status
Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.[1]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 "Filspari- sparsentan tablet, film coated". DailyMed. 17 February 2023. Archived from the original on 7 March 2023. Retrieved 6 March 2023.
- ↑ "February 2023 decisions expected from the FDA". Prime Therapeutics LLC. Archived from the original on 27 January 2023. Retrieved 24 May 2023.
External links
| Identifiers: |
|---|
- Clinical trial number NCT03762850 for "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help MDWiki by expanding it. |
- Pages using duplicate arguments in template calls
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs not assigned an ATC code
- Orphan drugs
- RTT
- All stub articles
- Pharmacology stubs